Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review

Ge, Jin; Verma, Vivek; Hollander, Andrew; Langer, Corey J.; Simone, Charles B.

doi:10.21037/jtd.2016.12.102

Cited by 7 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rarely, radiation recall phenomena have been described in different internal organs, including the lungs, esophagus, central nervous system (brainstem and optic nerve), gastrointestinal tract, musculoskeletal systems, heart, bladder, salivary glands, supraglottis, vagina, and oral mucosa [ 14 - 17 ]. Ge et al [ 18 ] emphasized that RRD may be the most visible sign of radiation recall affecting internal organs. In five cases of RRD in thoracic malignancies, RRD was accompanied by clinical and/or radiographic evidence of internal organ involvement [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

Sorafenib is widely used for unresectable and metastatic hepatocellular carcinomas. Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to previously irradiated skin that occurs after the administration of certain drugs. RRD after sorafenib treatment is rare; five cases have been reported thus far. We describe a 44-year-old man irradiated for chest wall bone metastasis from hepatocellular carcinoma. Eight days after radiotherapy completion, systemic therapy for metastatic hepatocellular carcinoma was initiated with sorafenib treatment. Eleven days after starting sorafenib, the patient complained of erythematous rash with pruritus in the chest wall, in a location consistent with the previous radiation field. Sorafenib was continued at the same dose, despite the RRD. The skin reaction subsided over the next 2 weeks without any medical intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Ge et al [ 18 ] emphasized that RRD may be the most visible sign of radiation recall affecting internal organs. In five cases of RRD in thoracic malignancies, RRD was accompanied by clinical and/or radiographic evidence of internal organ involvement [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although we cannot draw definitive conclusions based on the limited data [ 14 , 15 ], this finding indicated that the occurrence of RRP might be related to favorable response to PD-1/PD-L1 blockade immunotherapy. However, chemo-induced RRP was not found to be related to the therapeutic effect of chemotherapy [ 20 , 21 , 25 ].…”

Section: Main Textmentioning

confidence: 99%

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications

Teng

2020

BMC Med

View full text Add to dashboard Cite

Background The synergistic effect of radiotherapy (RT) in combination with immunotherapy has been shown in several clinical trials and case reports. The overlapping pulmonary toxicity induced by thoracic RT and programmed death 1/programmed death ligand-1 (PD-1/PD-L1) blockades is an important issue of clinical investigation in combination treatment. Thus far, the underlying mechanism of this toxicity remains largely unknown. Main text In this review, we discuss the unique pattern of radiation recall pneumonitis (RRP) induced by PD-1 blockade. The clinical presentation is different from common radiation pneumonitis (RP) or RRP induced by cytotoxic drugs. The immune checkpoint inhibitors may evoke an inflammatory reaction in patients’ previously irradiated fields, with infiltrating lymphocytes and potential involvement of related cytokines. All RRP patients have showed durable response to anti-PD-1/PD-L1. RRP is manageable; however, interruption of checkpoint blockades is necessary and immunosuppressive treatment should be started immediately. Further analyses of the predictive factors, including RT dosimetric parameters, tumor-infiltrating lymphocytes (TILs), and PD-L1 expression, are needed given the wide use of immune checkpoint inhibitors and high mortality from lung toxicity with the combination treatment. Conclusion Immune checkpoint inhibitors may evoke an RRP in the patients’ previously irradiated fields. Interactions between immune checkpoint inhibitors and radiotherapy should be studied further.

show abstract

Cutaneous Side Effects of Chemotherapy and Radiotherapy

Fearfield,

Edwards

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

The number of people diagnosed with cancer each year continues to rise, with an estimated one in two people likely to be affected in their lifetime. Chemotherapy and radiotherapy are crucial to cancer management; however, treatments are commonly associated with skin toxicity. In this chapter we summarise the key features, diagnosis and treatments associated with the commonest skin‐related adverse effects.

show abstract

Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review

Cited by 7 publications

References 18 publications

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications

Cutaneous Side Effects of Chemotherapy and Radiotherapy

Contact Info

Product

Resources

About